Clinical Trial Update: Afatinib With CT and RT for EGFR-Mutant NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial at Massachusetts General Hospital is evaluating afatinib with concurrent chemotherapy and radiotherapy for EGFR-mutant non-small cell l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING